EVOGENE LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.635 USD | +0.16% |
|
-0.16% | -24.40% |
| Jun. 20 | Nir Arbel Steps Down as Chief Product Officer of Evogene Ltd | CI |
| May. 23 | Earnings Flash (EVGN) EVOGENE Posts Q1 Revenue $4.2M, vs. Street Est of $3.5M | MT |
Financials (USD)
| Sales 2024 * | 14.99M | Sales 2025 * | 25.85M | Capitalization | 31.89M |
|---|---|---|---|---|---|
| Net income 2024 * | -22M | Net income 2025 * | -19M | EV / Sales 2024 * | 2.13 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.23 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 142 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Evogene Ltd.
More press releases
| 1 day | +0.16% | ||
| 1 week | -0.16% | ||
| Current month | -2.37% | ||
| 1 month | -3.82% | ||
| 3 months | -14.54% | ||
| 6 months | -32.30% | ||
| Current year | -24.40% |
1 week
0.61
0.65
1 month
0.610.72
Current year
0.611.04
1 year
0.451.43
3 years
0.453.58
5 years
0.4510.24
10 years
0.4515.50
| Managers | Title | Age | Since |
|---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01-12-31 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 22-03-31 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 04-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 21-11-16 |
Sarit Firon
CHM | Chairman | 58 | 16-08-10 |
Leon Recanati
BRD | Director/Board Member | 76 | 05-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-12 | 0.635 | +0.16% | 34,425 |
| 24-07-11 | 0.634 | +1.41% | 224,404 |
| 24-07-10 | 0.6252 | -2.16% | 120,096 |
| 24-07-09 | 0.639 | +0.61% | 117,070 |
| 24-07-08 | 0.6351 | -0.14% | 129,841 |
Delayed Quote Nasdaq, July 12, 2024 at 04:00 pm EDT
More quotes
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +22.10% | 46.55B | |
| +46.45% | 41.84B | |
| -3.12% | 40.84B | |
| +36.10% | 32.95B | |
| -6.30% | 28.27B | |
| +18.71% | 27.78B | |
| +46.15% | 14.26B | |
| +44.52% | 13.69B | |
| +0.19% | 12.18B |
- Stock Market
- Equities
- EVGN Stock
- EVGN Stock
